Laura Oliphant, a director at Aehr Test Systems (NASDAQ: AEHR), sold 4,665 shares of the company's stock on April 16, 2026, for a total of $399,267 at a price of $85.59 per share. This sale follows an impressive 891% increase in the stock's value over the past year, although it is currently trading at $80.85, below the sale price. Aehr Test Systems has recently announced a record $41 million production order from a hyperscale customer for package-level testing of custom AI processor ASICs, marking the largest order in the company's history. Despite mixed financial results for Q3 2026, where the company reported an earnings per share of -$0.05, better than the expected -$0.07, it missed revenue forecasts with $10.3 million against an expected $10.8 million. Analysts have responded positively to Aehr's strong bookings momentum, with Freedom Broker raising its price target to $61 and Lake Street to $56, both maintaining favorable ratings. The company reported $37.2 million in quarterly bookings and has an effective backlog exceeding $50 million, highlighting its strategic positioning in the AI market.